United Therapeutics Corporation - Common Stock · Transaction Oct 31, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · UTHR
-1.48% · -$7.69 · Vol 415.6K
Market closed · last close 4:00 PM ET · price as of 16:53:33 ET
United Therapeutics Corp
Biotechnology
$513.31
Veridion Score
Refresh
Score snapshot refresh in progress
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for UTHR until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
SovereignWhy is UTHR moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About United Therapeutics Corp
PHARMACEUTICAL PREPARATIONSListed since
1999
Employees
1K
Country
US
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$523.23
Day high
$528.02
Day low
$512.29
Previous close
$521.00
52W high
$596.76
-13.98% from high
52W low
$304.76
71% of range
Market cap
$22.3B
P/E
19.64×
EPS
$26.13
Beta
0.00
Shares out
42.9M
Volume
415.6K
0.86× rel vol
Avg volume
481K
VWAP
$517.79
Price history computed in-house
1W
+2.72%
1M
-3.06%
3M
-9.70%
1Y
+64.40%
YTD
+5.35%
SMA 50 $533.06 · below
SMA 200 $520.85 · below
52W position 71%
UTHR overview
Related filings and maps
Public disclosures
Congress activity in UTHR
Official filing ↗
United Therapeutics Corporation - Common Stock · Transaction Oct 30, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
United Therapeutics Corporation - Common Stock · Transaction Oct 30, 2025 · Filed Nov 21, 2025 · $1,001 to $15,000
UTHR Common Stock · Transaction Oct 27, 2025 · Filed Nov 10, 2025 · Amount pending receipt enrichment
UTHR Common Stock · Transaction Aug 22, 2025 · Filed Sep 11, 2025 · Amount pending receipt enrichment
Federal contracts
UTHR contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for UTHR in this window.
Lobbying spend
UTHR lobbying filings, year to date.
Registered lobbying filings matched to United Therapeutics Corp.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for UTHR in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for UTHR.
Options
Sovereign unlock shows live options positioning for UTHR.